1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Weiss, M.A.
Hua, Q.X.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Biol.Chem.
JBCHA3
0071
0021-9258
279
21449
21460
10.1074/jbc.M314141200
14988398
Mechanism of insulin fibrillation: the structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate
2004
10.2210/pdb1sf1/pdb
pdb_00001sf1
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
2383.698
INSULIN A CHAIN
1
man
polymer
3433.953
Insulin
1
man
polymer
no
no
GIVEQCCTSICSLYQLENYCN
GIVEQCCTSICSLYQLENYCN
A
polypeptide(L)
no
no
FVNQHLCGSHLVEALYLVCGERGFFYTPKT
FVNQHLCGSHLVEALYLVCGERGFFYTPKT
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
Escherichia
sample
9606
Homo sapiens
562
Escherichia coli
human
Homo
Escherichia
sample
INS
9606
Homo sapiens
562
Escherichia coli
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
2004-03-30
1
1
2008-04-29
1
2
2011-07-13
1
3
2022-03-02
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
NMR Structure Of Human Insulin In 20% Acetic Acid, Zinc-Free, 10 Structures: Native human insulin at 25 degree,
NMR solution structure
RCSB
Y
RCSB
2004-02-19
REL
REL
THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR AND 15N-3D HETERONUCLEAR NMR TECHNIQUES.
structures with the lowest energy
40
15
2D TOCSY
NOESY
COSY
3D_15N-separated_NOESY
2.4
ambient
333
K
RMSD VALUES FOR ALL 15 STRUCTURES VERSUS GEOMETRIC AVERAGE: (BACKBONE, A2-A20, B4-B24) 2.27 ANGSTROM
DISTANCE GEOMETRY AND SIMULATED ANNEALING
1
closest to the average
0.5 mM 15N-labeled sample
pH 2.4 and 60C, 90% H2O/10%D2O
BRUNGER
refinement
X-PLOR
2.1
Varian
structure solution
VNMR 6.1B
6.1B
800
Bruker
DRX
600
Varian
INOVA
GLY
1
n
1
GLY
1
A
ILE
2
n
2
ILE
2
A
VAL
3
n
3
VAL
3
A
GLU
4
n
4
GLU
4
A
GLN
5
n
5
GLN
5
A
CYS
6
n
6
CYS
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
SER
9
n
9
SER
9
A
ILE
10
n
10
ILE
10
A
CYS
11
n
11
CYS
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
TYR
14
n
14
TYR
14
A
GLN
15
n
15
GLN
15
A
LEU
16
n
16
LEU
16
A
GLU
17
n
17
GLU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
PHE
1
n
1
PHE
1
B
VAL
2
n
2
VAL
2
B
ASN
3
n
3
ASN
3
B
GLN
4
n
4
GLN
4
B
HIS
5
n
5
HIS
5
B
LEU
6
n
6
LEU
6
B
CYS
7
n
7
CYS
7
B
GLY
8
n
8
GLY
8
B
SER
9
n
9
SER
9
B
HIS
10
n
10
HIS
10
B
LEU
11
n
11
LEU
11
B
VAL
12
n
12
VAL
12
B
GLU
13
n
13
GLU
13
B
ALA
14
n
14
ALA
14
B
LEU
15
n
15
LEU
15
B
TYR
16
n
16
TYR
16
B
LEU
17
n
17
LEU
17
B
VAL
18
n
18
VAL
18
B
CYS
19
n
19
CYS
19
B
GLY
20
n
20
GLY
20
B
GLU
21
n
21
GLU
21
B
ARG
22
n
22
ARG
22
B
GLY
23
n
23
GLY
23
B
PHE
24
n
24
PHE
24
B
PHE
25
n
25
PHE
25
B
TYR
26
n
26
TYR
26
B
THR
27
n
27
THR
27
B
PRO
28
n
28
PRO
28
B
LYS
29
n
29
LYS
29
B
THR
30
n
30
THR
30
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
5
B
B
O
H
HIS
CYS
5
7
1.52
5
B
B
O
H
GLU
TYR
13
16
1.55
6
B
B
O
H
CYS
GLY
19
23
1.47
1
B
ARG
22
0.222
SIDE CHAIN
2
B
ARG
22
0.316
SIDE CHAIN
3
B
ARG
22
0.314
SIDE CHAIN
4
B
ARG
22
0.248
SIDE CHAIN
5
B
ARG
22
0.279
SIDE CHAIN
6
B
ARG
22
0.318
SIDE CHAIN
7
B
ARG
22
0.166
SIDE CHAIN
8
B
ARG
22
0.260
SIDE CHAIN
9
B
ARG
22
0.313
SIDE CHAIN
10
B
ARG
22
0.293
SIDE CHAIN
11
B
ARG
22
0.293
SIDE CHAIN
12
B
ARG
22
0.317
SIDE CHAIN
13
B
ARG
22
0.312
SIDE CHAIN
14
B
ARG
22
0.298
SIDE CHAIN
15
B
ARG
22
0.230
SIDE CHAIN
1
-32.05
2.10
120.10
88.05
A
A
A
CA
C
O
ASN
ASN
ASN
21
21
21
N
13
-20.47
2.10
120.10
99.63
A
A
A
CA
C
O
ASN
ASN
ASN
21
21
21
N
4
A
A
C
O
ASN
ASN
21
21
0.161
0.019
1.229
1.390
N
13
A
A
C
O
ASN
ASN
21
21
0.200
0.019
1.229
1.429
N
1
A
THR
8
161.65
44.83
1
A
SER
9
161.27
106.14
1
A
ILE
10
82.09
177.37
1
A
CYS
11
73.91
122.36
1
A
SER
12
169.30
61.66
1
A
LEU
13
62.91
87.74
1
A
TYR
14
164.98
-51.14
1
A
LEU
16
-70.28
-125.71
1
A
GLU
17
46.19
26.17
1
A
ASN
18
175.15
30.83
1
B
CYS
7
53.61
-177.66
1
B
PHE
25
-73.64
-74.32
2
A
GLU
4
68.55
83.08
2
A
GLN
5
176.03
130.35
2
A
CYS
6
-42.78
-83.68
2
A
THR
8
176.70
60.33
2
A
SER
9
-171.37
25.53
2
A
ILE
10
52.38
110.00
2
A
CYS
20
-157.89
77.51
2
B
ASN
3
-174.97
65.31
2
B
CYS
7
162.61
48.58
2
B
GLU
21
64.89
-173.04
2
B
ARG
22
75.24
67.32
2
B
PHE
24
67.44
138.37
2
B
PHE
25
178.32
-68.36
2
B
THR
27
61.81
146.45
3
A
GLU
4
-126.52
-129.01
3
A
GLN
5
-56.16
-91.44
3
A
CYS
6
161.88
101.89
3
A
CYS
7
-159.50
-36.05
3
A
SER
9
163.69
-77.09
3
A
CYS
11
-153.05
81.92
3
A
LEU
16
-79.86
-119.96
3
A
GLU
17
44.67
27.52
3
A
ASN
18
-171.38
35.53
3
B
ASN
3
-54.88
-175.46
3
B
GLN
4
-91.66
53.74
3
B
LEU
6
-114.94
-164.31
3
B
CYS
7
60.12
-169.41
3
B
SER
9
78.17
-3.32
3
B
GLU
13
-100.59
-72.92
3
B
GLU
21
60.98
-86.98
3
B
TYR
26
-123.63
-126.74
4
A
ILE
2
-93.52
48.93
4
A
GLU
4
-159.57
55.65
4
A
GLN
5
-148.10
-33.81
4
A
CYS
6
67.76
92.00
4
A
CYS
7
-159.98
-34.02
4
A
SER
9
171.06
-56.99
4
A
ILE
10
164.93
127.31
4
A
LEU
16
-69.76
-110.58
4
A
GLU
17
43.73
29.60
4
A
ASN
18
-164.30
-32.80
4
A
CYS
20
-173.06
83.85
4
B
VAL
2
-147.25
51.84
4
B
HIS
5
30.21
56.38
4
B
LEU
6
-112.95
-167.92
4
B
CYS
7
60.95
-171.97
4
B
SER
9
78.27
-2.76
4
B
GLU
13
-67.91
-78.50
4
B
GLU
21
46.87
75.43
4
B
PHE
25
-74.76
-72.05
4
B
TYR
26
66.20
68.72
4
B
THR
27
46.28
92.88
4
B
LYS
29
56.78
-171.21
5
A
GLU
4
-175.48
72.15
5
A
THR
8
173.22
-30.42
5
A
SER
9
116.66
58.54
5
A
ILE
10
-162.25
84.44
5
A
CYS
11
178.27
70.29
5
A
LEU
16
-69.59
-119.20
5
A
GLU
17
45.17
26.70
5
A
ASN
18
-167.87
24.15
5
A
CYS
20
-164.23
48.32
5
B
ASN
3
179.89
107.78
5
B
GLN
4
56.63
83.76
5
B
HIS
5
-43.60
151.46
5
B
LEU
6
-60.92
50.49
5
B
CYS
7
-159.49
73.69
5
B
GLU
13
-59.59
-80.57
5
B
LEU
17
177.83
-32.83
5
B
GLU
21
-40.01
95.58
5
B
ARG
22
179.16
-43.60
5
B
PHE
25
-57.07
91.01
5
B
THR
27
178.39
134.02
5
B
LYS
29
-135.36
-81.08
6
A
ILE
2
178.92
139.02
6
A
VAL
3
-59.08
170.61
6
A
GLU
4
-128.26
-126.24
6
A
GLN
5
161.58
-172.24
6
A
CYS
6
-48.35
-87.35
6
A
CYS
7
-121.36
-60.89
6
A
THR
8
174.63
86.23
6
A
SER
9
166.32
-64.99
6
A
ILE
10
178.16
144.01
6
A
CYS
11
-151.71
64.38
6
A
LEU
16
-70.83
-126.38
6
A
GLU
17
45.55
26.78
6
A
ASN
18
174.56
-88.87
6
A
CYS
20
-145.60
56.43
6
B
HIS
5
-178.27
113.76
6
B
CYS
7
35.29
54.88
6
B
GLU
13
-52.51
-72.65
6
B
ARG
22
-130.53
-36.65
6
B
PHE
25
-178.80
31.72
6
B
THR
27
173.06
99.55
6
B
LYS
29
50.41
-171.85
7
A
ILE
2
41.69
-169.20
7
A
GLU
4
-175.70
51.07
7
A
GLN
5
-163.53
96.59
7
A
CYS
6
-59.84
-92.50
7
A
THR
8
163.39
32.38
7
A
SER
9
157.01
-85.41
7
A
CYS
11
149.59
68.43
7
A
SER
12
-103.17
45.46
7
A
TYR
14
-149.61
-69.81
7
A
LEU
16
-74.88
-116.36
7
A
GLU
17
41.27
29.22
7
A
ASN
18
167.02
-64.07
7
A
TYR
19
46.72
26.22
7
B
GLN
4
60.88
68.14
7
B
GLU
13
-50.16
-75.70
7
B
PHE
25
-179.48
74.65
7
B
TYR
26
179.83
46.14
8
A
GLU
4
-163.45
47.35
8
A
CYS
7
-151.18
12.94
8
A
THR
8
-158.43
23.47
8
A
SER
9
161.72
37.72
8
A
ILE
10
55.67
165.60
8
A
SER
12
56.22
164.40
8
A
GLN
15
-91.86
-69.41
8
A
LEU
16
-62.11
-140.54
8
A
GLU
17
48.02
22.58
8
A
ASN
18
158.35
31.06
8
A
CYS
20
-145.71
-96.17
8
B
ASN
3
-177.16
-174.32
8
B
GLN
4
-162.25
55.83
8
B
CYS
7
39.57
-168.23
8
B
GLU
13
-52.00
-70.62
8
B
ARG
22
33.65
49.62
8
B
PHE
25
35.24
-114.44
8
B
TYR
26
166.21
49.21
8
B
LYS
29
-169.89
107.22
9
A
VAL
3
-62.35
-172.39
9
A
GLU
4
66.19
72.95
9
A
GLN
5
-55.15
-164.25
9
A
CYS
7
-133.95
-38.82
9
A
THR
8
-117.66
58.34
9
A
SER
9
173.17
-81.42
9
A
ILE
10
177.45
154.70
9
A
CYS
11
-171.18
87.04
9
A
SER
12
-113.45
65.33
9
A
LEU
13
76.92
-48.55
9
A
LEU
16
-68.93
-122.77
9
A
GLU
17
42.89
27.54
9
A
ASN
18
167.95
38.09
9
B
ASN
3
54.38
100.55
9
B
GLN
4
-105.68
51.35
9
B
CYS
7
43.62
-168.44
9
B
SER
9
77.31
-3.26
9
B
ARG
22
-135.50
-153.88
9
B
PHE
24
59.90
85.39
9
B
PHE
25
-99.99
-94.40
9
B
TYR
26
161.94
57.03
9
B
THR
27
-165.38
95.05
10
A
GLU
4
77.48
49.18
10
A
GLN
5
-162.59
18.41
10
A
THR
8
178.84
29.72
10
A
LEU
16
-79.49
-124.76
10
A
GLU
17
45.98
25.91
10
A
ASN
18
179.38
29.49
10
A
CYS
20
175.59
-29.64
10
B
VAL
2
44.92
82.60
10
B
ASN
3
179.61
89.35
10
B
GLN
4
-94.91
54.20
10
B
LEU
6
-41.88
165.56
10
B
CYS
7
37.10
94.73
10
B
HIS
10
-102.45
-63.93
10
B
GLU
21
161.81
-38.60
10
B
ARG
22
-65.78
-167.91
10
B
PHE
24
-171.65
147.67
10
B
THR
27
-171.38
71.65
11
A
GLU
4
77.48
49.18
11
A
GLN
5
-162.59
18.41
11
A
THR
8
178.84
29.72
11
A
LEU
16
-79.49
-124.76
11
A
GLU
17
45.98
25.91
11
A
ASN
18
179.38
29.49
11
A
CYS
20
175.59
-29.64
11
B
VAL
2
44.92
82.60
11
B
ASN
3
179.61
89.35
11
B
GLN
4
-94.91
54.20
11
B
LEU
6
-41.88
165.56
11
B
CYS
7
37.10
94.73
11
B
HIS
10
-102.45
-63.93
11
B
GLU
21
161.81
-38.60
11
B
ARG
22
-65.78
-167.91
11
B
PHE
24
-171.65
147.67
11
B
THR
27
-171.38
71.65
12
A
VAL
3
-56.70
179.86
12
A
GLU
4
69.45
85.50
12
A
CYS
6
-153.69
-108.40
12
A
CYS
7
-98.63
-72.41
12
A
THR
8
166.26
34.39
12
A
SER
9
158.03
-48.25
12
A
CYS
11
161.39
50.70
12
A
GLN
15
-106.05
-70.53
12
A
LEU
16
-61.71
-142.72
12
A
GLU
17
55.84
19.29
12
A
ASN
18
165.99
39.45
12
A
CYS
20
-147.98
-95.77
12
B
VAL
2
60.53
115.39
12
B
GLN
4
174.76
86.53
12
B
LEU
6
79.29
154.61
12
B
SER
9
145.12
-7.19
12
B
ARG
22
-46.70
-73.60
13
A
ILE
2
-114.29
63.44
13
A
GLU
4
-165.63
75.90
13
A
GLN
5
177.98
-142.30
13
A
CYS
6
-163.15
-98.32
13
A
THR
8
174.21
74.05
13
A
SER
9
169.18
31.33
13
A
ILE
10
58.85
145.95
13
A
CYS
11
-159.65
60.62
13
A
ASN
18
-148.39
55.67
13
A
CYS
20
-72.85
-74.92
13
B
GLN
4
177.60
76.39
13
B
HIS
5
55.25
80.32
13
B
LEU
6
-46.38
172.36
13
B
CYS
7
57.25
107.15
13
B
SER
9
-170.58
-60.74
13
B
CYS
19
-94.07
-64.75
13
B
GLU
21
-165.82
-168.50
13
B
ARG
22
-52.48
176.07
13
B
PHE
25
53.46
-92.48
13
B
TYR
26
43.89
71.74
13
B
THR
27
-48.70
150.24
14
A
THR
8
-171.77
59.11
14
A
SER
9
162.65
50.87
14
A
ILE
10
47.47
-176.52
14
A
CYS
11
-152.33
62.56
14
A
LEU
16
-75.45
-123.82
14
A
GLU
17
44.74
27.97
14
A
ASN
18
173.44
100.22
14
A
TYR
19
-179.76
39.22
14
A
CYS
20
-174.18
36.57
14
B
VAL
2
64.15
94.98
14
B
LEU
6
-165.82
62.49
14
B
CYS
7
-108.27
55.23
14
B
GLU
13
-53.75
-70.62
14
B
PHE
24
176.99
132.52
14
B
PHE
25
-146.10
17.88
14
B
TYR
26
43.82
74.00
15
A
GLU
4
-176.16
86.88
15
A
GLN
5
177.47
-165.11
15
A
CYS
6
-90.96
-104.26
15
A
CYS
7
-93.69
-64.30
15
A
THR
8
-174.86
85.78
15
A
SER
9
164.90
58.57
15
A
ILE
10
62.03
147.33
15
A
CYS
11
172.44
47.95
15
A
LEU
13
-45.12
-74.49
15
A
GLN
15
84.59
-17.22
15
A
LEU
16
-106.78
-129.61
15
A
GLU
17
44.45
26.66
15
A
ASN
18
176.40
-79.86
15
B
GLN
4
42.85
75.35
15
B
HIS
5
179.20
97.20
15
B
CYS
7
55.21
-178.46
15
B
SER
9
54.53
19.17
15
B
GLU
13
-46.00
-73.63
15
B
GLU
21
63.04
139.29
15
B
ARG
22
170.48
-37.51
15
B
PHE
24
41.36
85.03
NMR STRUCTURE OF HUMAN INSULIN under Amyloidogenic Condition, 15 STRUCTURES
1
N
N
2
N
N
A
TYR
14
A
TYR
14
HELX_P
A
TYR
19
A
TYR
19
1
1
6
B
SER
9
B
SER
9
HELX_P
B
CYS
19
B
CYS
19
1
2
11
disulf
2.021
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
11
A
SG
CYS
11
1_555
disulf
2.020
A
CYS
7
A
SG
CYS
7
1_555
B
CYS
7
B
SG
CYS
7
1_555
disulf
2.020
A
CYS
20
A
SG
CYS
20
1_555
B
CYS
19
B
SG
CYS
19
1_555
HORMONE/GROWTH FACTOR
HORMONE, HUMAN INSULIN, HORMONE-GROWTH FACTOR COMPLEX
INS_HUMAN
UNP
1
90
P01308
GIVEQCCTSICSLYQLENYCN
INS_HUMAN
UNP
2
25
P01308
FVNQHLCGSHLVEALYLVCGERGFFYTPKT
90
110
1SF1
1
21
P01308
A
1
1
21
25
54
1SF1
1
30
P01308
B
2
1
30
1
P 1